Reversal of Marrow Fibrosis Following Imatinib Mesylate Therapy in a Patient with Chronic Myelogenous Leukemia Who Was Refractory to Interferon--α

Abstract

Bone marrow fibrosis is associated with a poor prognosis in those patients with chronic myelogenous leukemia (CML). It is present at the initial diagnosis as well as during CML transformation. Although the effect of interferon-α therapy on marrow fibrosis has been controversial, imatinib mesylate has shown significant activity to reduce the CML-associated bone marrow fibrosis as well as the Philadelphia chromosome-positive cells. We report here on a case of the reversal of marrow fibrosis after imatinib mesylate therapy in a 67 year-old female patient suffering with CML that was refractory to interferon-α. 2)만성골수성백혈병에서 병발하는 골수섬유화는 진단 초기도 발견되지만 만성기에서 가속기와 급성기로 형